Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively.
The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.
Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.
In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.
The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth.
For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.
Small Molecule Innovator API CDMO Market Report Highlights
- The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth
- Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases
- The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment
- Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 241 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $29.94 Billion |
| Forecasted Market Value (USD) by 2030 | $47.14 Billion |
| Compound Annual Growth Rate | 6.5% |
Market Dynamics
Market driver analysis
- Increasing Demand for Small Molecule Drugs
- Increasing Outsourcing Trends Among Pharmaceutical Companies
- Surge in Number of Clinical Trials
Market restraint analysis
- Compliance Issues While Outsourcing
- Changing Scenarios in Developing Economies
Technology Landscape
- Integration Of Ai In Small Molecule Innovator API CDMO Market
Current Dynamics and Future Trends
- Drug Discovery and Design
- AI-Assisted Drug API Synthesis
- Process Optimization
- Supply Chain Management
- Clinical Trial Optimization
- Regulatory Compliance
Total Number of Clinical Trials by Phase & Region (2021 - 2023)
- Total Number of Clinical Trials by Phase (2021 - 2023)
- Total Number of Clinical Trials by Region (2021 - 2023)
- Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
Small Molecule Innovator API CDMO Market: Analysis Tools
- Porter's Five Forces Analysis
- PESTEL Analysis
Impact of COVID-19 on Small Molecule Innovator CDMO Market
COVID-19 Impact Analysis
Competitive Landscape
- Lonza Group Ltd.
- Novo Holdings (Catalent, Inc.)
- Thermo Fisher Scientific, Inc.
- Siegfried Holding AG
- Recipharm AB
- CordenPharma International
- Samsung Biologics
- Labcorp
- Ajinomoto Bio-Pharma Services
- Piramal Pharma Solutions
- Jubilant Life Sciences (Jubilant Biosys Limited)
- WuXi AppTec Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/rhi77g
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
